製品名:(3-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazol-5-yl)methyl acetate

IUPAC Name:[3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2-oxazol-5-yl]methyl acetate

CAS番号:1380089-34-8
分子式:C13H20BNO5
純度:97%
カタログ番号:CM208606
分子量:281.12

包装単位 有効在庫 価格(USD) 数量
CM208606-1g in stock Žǟř

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:1380089-34-8
分子式:C13H20BNO5
融点:-
SMILESコード:CC(OCC1=C(B2OC(C)(C)C(C)(C)O2)C(C)=NO1)=O
密度:
カタログ番号:CM208606
分子量:281.12
沸点:
MDL番号:
保管方法:

Category Infos

Boronic Acids and Esters
Boronic acids and boronate esters are commonly used reagents in Suzuki–Miyaura coupling chemistry. Organoboron derivatives are common reagents for C–C bond formation, either through classical palladium-mediated transformations or through other newer coupling methods. Boronic esters and acids are potential intermediates in the manufacture of many active pharmaceutical ingredients (API).
Boronic Acid For Sale
Find trusted boronic acid for sale. Any requirements and problems can ask us at any time.
Isoxazoles
Isoxazole is a liquid heterocyclic compound C3H3NO isomeric with oxazole and having a penetrating odor like that of pyridine. Isoxazoles belong to an important class of five-membered aromatic heterocycles containing two electronegative heteroatoms, nitrogen and oxygen, in a 1,2-relationship and three regular sp2 carbon atoms. These molecules are found to be key components in various synthetic products in daily use and also present as a pharmacophore essential for biological activity in many drugs and bioactive natural products. In addition, isoxazoles have demonstrated their ability to exhibit hydrogen bond donor/acceptor interactions with a variety of enzymes and receptors.

Column Infos

Pelabresib
MorphoSys’ phase 3 study of Pelabresib in myelofibrosis demonstrates statistically significant improvement in spleen volume reduction and strong positive trend in symptom reduction.
Pelabresib (CPI-0610) is an investigational selective small molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain (BET) proteins to decrease the expression of abnormally expressed genes in cancer. MorphoSys intends to submit for approval in the U.S. and Europe in mid-2024.

Related Products